Última actualización: Agosto 17, 2026
Productos de inmunoterapia a base de células
Abecma
BIO DEL PÁJARO AZUL
A chimeric antigen receptor (AUTO) Terapia con células T para adultos con mieloma múltiple en recaída o refractario. Aprobado por la FDA de EE. UU. en marzo 2021. Aprobado por Health Canada en mayo 2021. Aprobado por la EMA en agosto 2021. Aprobado para su uso en Japón en febrero. 2022.
APCeden
APAC BIOTECH
APCeden is an autologous monocyte-derived mature dendritic cell vaccine. It was approved in India in 2017 for the treatment of prostate cancer, ovarian cancer, colorectal cancer, and Non Small Cell Lung carcinoma.
Breyanzi
BRISTOL MYERS SQUIBB
Breyanzi is a CAR T-cell therapy for adults with relapsed or refractory large B-cell lymphoma. It is approved by the US FDA for adult patients with relapsed or refractory diffuse large B-cell lymphoma (Febrero 2021), and again for r/r large B-cell lymphoma as second line treatment (Junio 2022). It is approved by the European Commission for use in adult patients with r/r large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (Abril 2022).
Carteyva
JW THERAPEUTICS
Carteyva is an autologous anti-CD19 CAR-T cell immunotherapy drug. It was approved by China’s NMPA in 2021 to treat adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Carvykti
LEGEND BIOTECH & JANSSEN
Carvykti is a CAR-T cell therapy used for adult patients who have cancer of the bone marrow called multiple myeloma. It was approved in the U.S. in February of 2022 to treat relapsed or refractory multiple myeloma after four or more prior lines of therapy. It was also approved in the European Union in May of 2022 to treat relapsed or refractory multiple myeloma for adult patients who received at least three prior therapies.
CreaVax RCC
JW CREAGENE
A dendritic cell based vaccine intended to treat metastatic renal cell carcinoma for which nephrectomy can be performed. Aprobado en S. Korea in S. Corea en 2007.
Immuncell-LC
GC PHARMA
A medicine for anticancer cell immunotherapy, made with T-lymphocyte incubated and activated after extraction from the blood of a patient. Conditionally approved in S. Korea in June 2007.
Kymriah
NOVARTIS
Kymriah is a CAR T-cell therapy product approved in the US for the treatment of acute lymphoblastic leukemia (TODO), chronic lymphoid leukemia and diffuse large B-cell lymphoma in patients up to 25 años de edad, (FDA de EE. UU., Agosto 2017) the treatment of adult patients with relapse/refractory (r/r) large B-cell lymphoma, (FDA de EE. UU., Puede 2018) and the treatment of adult patients with (r/r) follicular lymphoma. (FDA de EE. UU., Puede 2022)
It also received EU marketing authorisation for these indications by the European Commission in August 2018, and by Health Canada in September 2018.
It was approved in Japan for the treatment of ALL in February 2019 and in Singapore in 2021.
Provenge
DENDREON
Autologous Cellular Immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. BLA approved by the FDA in 2010.
Tecartus
KITE, A GILEAD COMPANY
Tecartus is a CAR-T therapy designed to treat mantle cell lymphoma. It was approved in the US in July 2020 and in the EU in December 2020.
Yescarta
KITE, A GILEAD COMPANY
Yescarta is a CAR T-cell therapy product indicated for the treatment of B cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphoid leukemia and diffuse large B-Cell lymphoma. Aprobado por EE.UU.. FDA in October 2017. Approved by the EC in August 2018. Approved by Health Canada in February 2019. Approved in Japan in January 2021, and in China in June 2021.
Yescarta was approved for additional indications to treat follicular lymphoma (FDA de EE. UU., Marzo 2021) and r/r large B-cell lymphoma (FDA de EE. UU., Abril 2022). It was also approved for additional indications to treat r/r follicular lymphoma (UE, Junio 2022) in the European Union.
Revisión de casos científicos
¿Le gustaría saber si los programas clínicos actuales, desarrollos recientes de investigación, o enfoques emergentes pueden ser relevante para su situación individual?
Comparte tu pregunta con nuestro equipo de investigación científica y recibe información centrada en las áreas de investigación actuales que pueden ser relevante para su caso.
- Revisión de la información que proporcionas.
- Información relevante sobre programas clínicos y de investigación.
- Una respuesta clara y centrada en tu situación.
Sin compromiso. Su pregunta será revisada de forma confidencial..
Información educativa y de investigación únicamente.. Este servicio no constituye consejo médico, diagnóstico, prescripción, o un personalizado recomendación de tratamiento.
